The emerging biopharmaceutical company is headquartered in Munich, Germany, and was founded in 2015. Its technology, invented by Prof. Dr. Hansjörg Eibl, has been applied in various in vitro and in vivo studies by a research group at the University Hospital of the Ludwig-Maximilians-Universitaet Munich. The company's drug development platform is designed to improve antitumor responses in cancer treatment by exploiting a novel mechanism of action called intravascular drug release. This allows for targeted chemotherapy, which treats locally advanced solid tumors with low side effects and increased efficacy.